We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Surgical outcomes of interval debulking surgery after neoadjuvant chemoimmunotherapy for advanced-stage ovarian cancer.
- Authors
Jung-Yun Lee; Jinhye Lee; Dahye Lee; Junsik Park; Sunghoon Kim
- Abstract
Objective: Korean Gynecologic Oncology Group 3046 constitutes a phase II trial evaluating the efficacy and safety of administering durvalumab and tremelimumab alongside neoadjuvant chemotherapy (NAC) to individuals diagnosed with front-line advanced-stage ovarian cancer. The primary objective of this investigation is to compare post-interval debulking surgery outcomes among patients undergoing neoadjuvant chemo-immunotherapy (paclitaxel-carboplatin-durvalumabtremelimumab) and those undergoing NAC (paclitaxelcarboplatin). Methods: In a retrospective cohort study, 29 women diagnosed with advanced-stage ovarian cancer underwent neoadjuvant chemoimmunotherapy, while 39 patients were treated with NAC during the same period at Yonsei University Health System. Statistical analyses, utilizing 2-sample nonparametric tests, aimed to evaluate disparities in postoperative transfusions, hospitalization duration, postoperative complications, and emergency department visits within a 30-day period between the two groups. Results: After comparing the group utilizing interval debulking surgery following neoadjuvant chemo-immunotherapy with the standard NAC group, no significant differences were observed in the mean operative time (405 minutes vs. 376 minutes, p=0.49) or postoperative hospitalization duration (10 days vs. 11 days, p=0.46). Additionally, although minor differences existed in presurgery hemoglobin levels (1.5 vs. 1.0, p=0.197) and emergency room visits within 30 days (14.3% vs. 17.9%, p=0.69) between the neoadjuvant chemo-immunotherapy and NAC groups, these distinctions did not achieve statistical significance. However, notably, the neoadjuvant chemo-immunotherapy group exhibited a significantly lower incidence of ileus (21.4% vs. 53.8%, p=0.008). Conclusion: Neoadjuvant chemo-immunotherapy appears to be safe and leads to favorable oncological outcomes. Postoperative complications observed in our study were not higher than those experienced by patients receiving NAC.
- Subjects
IMMUNOTHERAPY; YONSEI University; OVARIAN cancer; EMERGENCY room visits; GYNECOLOGIC oncology; NEOADJUVANT chemotherapy; SURGICAL complications
- Publication
Journal of Gynecologic Oncology, 2024, Vol 35, p10
- ISSN
2005-0380
- Publication type
Academic Journal
- DOI
10.3802/jgo.2024.35.S2.FP-OII1